TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT02926690: Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

Sponsor: OncoTherapy Science, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 70 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,193,808

Rescue Site Savings

+$785,400

Unlock Full NCT02926690 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT02926690 Rescue Dossier →